These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 25569270)
1. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Chen CX; Hay JW Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270 [TBL] [Abstract][Full Text] [Related]
2. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia. Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220 [TBL] [Abstract][Full Text] [Related]
3. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. Spencer SJ; Jones LK; Guzauskas GF; Hao J; Williams MS; Peterson JF; Veenstra DL J Clin Lipidol; 2022; 16(5):667-675. PubMed ID: 35961838 [TBL] [Abstract][Full Text] [Related]
6. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236 [TBL] [Abstract][Full Text] [Related]
7. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment. Ontario Health (Quality) Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868 [TBL] [Abstract][Full Text] [Related]
8. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment? Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Villa G; Lothgren M; Kutikova L; Lindgren P; Gandra SR; Fonarow GC; Sorio F; Masana L; Bayes-Genis A; Hout BV Clin Ther; 2017 Apr; 39(4):771-786.e3. PubMed ID: 28366593 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of the cost-effectiveness of population genetic screening for familial hypercholesterolemia in US patients. Hendy LE; Spees LP; Tak C; Carpenter DM; Thomas KC; Roberts MC Atherosclerosis; 2024 Jun; 393():117541. PubMed ID: 38677159 [TBL] [Abstract][Full Text] [Related]
11. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland. Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882 [TBL] [Abstract][Full Text] [Related]
12. The Cost-effectiveness of Genetic Screening for Familial Hypercholesterolemia: a Systematic Review. Rosso A; Pitini E; D'Andrea E; Massimi A; De Vito C; Marzuillo C; Villari P Ann Ig; 2017; 29(5):464-480. PubMed ID: 28715059 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness and Return on Investment of a Nationwide Case-Finding Program for Familial Hypercholesterolemia in Children in the Netherlands. Ademi Z; Norman R; Pang J; Sijbrands E; Watts GF; Hutten BA; Wiegman A JAMA Pediatr; 2023 Jun; 177(6):625-632. PubMed ID: 37126315 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: an Australian experience. Bell DA; Pang J; Burrows S; Bates TR; van Bockxmeer FM; Hooper AJ; O'Leary P; Burnett JR; Watts GF Atherosclerosis; 2015 Mar; 239(1):93-100. PubMed ID: 25585028 [TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales. Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685 [TBL] [Abstract][Full Text] [Related]
17. Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Marks D; Wonderling D; Thorogood M; Lambert H; Humphries SE; Neil HA Health Technol Assess; 2000; 4(29):1-123. PubMed ID: 11109029 [TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness of Screening Strategies for Familial Hypercholesterolaemia: An Updated Systematic Review. Marquina C; Morton JI; Lloyd M; Abushanab D; Baek Y; Abebe T; Livori A; Dahal P; Watts GF; Ademi Z Pharmacoeconomics; 2024 Apr; 42(4):373-392. PubMed ID: 38265575 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of a family and DNA based screening programme on familial hypercholesterolaemia in The Netherlands. Marang-van de Mheen PJ; ten Asbroek AH; Bonneux L; Bonsel GJ; Klazinga NS Eur Heart J; 2002 Dec; 23(24):1922-30. PubMed ID: 12473254 [TBL] [Abstract][Full Text] [Related]
20. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Jensen HK Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]